Kornimate/medical-research-clean huggingface dataset:
clinical trial for high intensity laser therapy (hilt) for elbow epicondylosis

Conditions: Chronic Pain; Elbow Tenderness; Elbow Pain Upon Active Resistive Motion

Summary: this study will determine the efficacy of high intensity laser therapy (hilt) for the treatment of elbow epicondylosis

the diagnosed patients with epicondylosis will be treated with hilterapia hiro 3.o for a total of four sessions during the entire duration of the treatment protocol. parameters to be evaluated are tenderness, pain upon active resistive motion and dash scores. after every treatment session of hilterapia hiro 3.o, these said parameters will be recorded initially on the first treatment, one week after the initial treatment, two weeks after the initial treatment and four weeks after the initial treatment. patient is advised to follow-up on the 6th and 12 month post initial hilterapia hiro 3.o treatment for the reevaluation of the parameters. tenderness is described as pain upon palpation and is further categorized into, 0= no tenderness, 1 = mild tenderness, 2 = tenderness evident on facial expression and 3 = patient screams upon palpation. pain is also noted upon active resistive motion of extension/flexion, supination/pronation. classification includes; 0 = no pain and 1 = mild pain with full power, 2 = severe pain with full power, and 3 = muscle weakness with pain. and for functional scoring will be using the dash which is a multidimensional disease specific, brief, self-administered measure of symptoms and functional status among subjects with upper limb disorders. the dash consists of a 30-item questionnaire with 5 response options for each item with a scale ranging from 0, which indicates "least disability," to 100, which indicates "most disability." a change in 12.7 dash score points is considered to represent clinically significant functional improvement.

Eligibility criteria:
inclusion criteria: * history of medial and lateral elbow pain for at least three months in duration * local tenderness for at least three months in duration * pain on the epicondyle upon active resistive flexion (medial) and extension (lateral) of the wrist exclusion criteria: * previous elbow conservative managements such as physical therapy and elbow injection-based therapies * previous surgical management of the elbow

Keywords: high intensity laser therapy elbow epicondylosis
rare subtypes of gastrointestinal cancers

Conditions: Cancer of Gastrointestinal Tract

Summary: a single-arm prospective observational translational study of biomarkers in patients receiving targeted treatment for rare subtypes of cancer of the gastrointestinal tract.

in this study, the investigators seek to investigate biological aspects in patients receiving targeted treatment for rare subtypes of cancer of the gastrointestinal. the targeted treatment will be given as per standard of care. translational blood samples will be drawn pre-treatment, before the third cycle of chemotherapy, and hereafter corresponding to the planned imaging during treatment and follow up. the total cell free dna will be quantified in all samples. the samples will be analyzed for tumor specific mutations such as the kras, braf, and nras oncogenes, by ddpcr. circulating tumor dna will also be identified by hypermethylation markers, and a focused panel of next generation sequencing can be applied. the samples will also be analyzed for immune-related biomarkers. the investigators expect to include up to 130 patients. this is a purely observational translational study. results will be analysed in relation to outcome data.

Eligibility criteria:
inclusion criteria: * diagnosis of a rare subtype of gi cancer including braf v600e mutation, msi-h, her2 and others * diagnosis of cancer of the gastrointestinal tract may be made by histo- or cyto-pathology, or by clinical and imaging criteria * planned for targeted treatment * age 18 years or older * able to understand written information * consent to samples for translational research exclusion criteria: * conditions precluding translational blood sampling * another concomitant cancer
summative usability study of cerebo® - a non invasive intracranial hemorrhage detector

Conditions: Usability

Summary: traumatic brain injury is one of the most common reasons for visits to the emergency department. more than 90% of patients who have suffered from head trauma present with a mild traumatic brain injury. most of these patients do not present any symptom at the time of diagnosis thus delaying the detection. cerebo®, a non-invasive, portable, rapid, point-of-care intracranial haemorrhage detector can avoid delayed detection by decreasing the time from injury to the initial ct scan. the study aims at assessing the summative usability of the device by determining its ease of use, ease of learning and satisfaction among the medical health professionals. the participants will be trained before the study and will be assessed periodically. each participant will use the device on at least 10 subjects.

a prospective interventional study designed to assess the summative usability and rapidity of cerebo® - a portable device to detect intracranial haemorrhage. 10 participants from a primary health centre will be enrolled in this study. the participants will be trained by the study staff before the study. the participant will fill in a questionnaire periodically. at the end of the study, the statistical analysis will be performed on the recorded data to establish the ease of use, ease of learning and satisfaction.

Eligibility criteria:
inclusion criteria: operators * medical health professionals \>18 years of age with a valid medical license to practice medicine belonging to one of the following categories and have given a written consent to participate in the study. * mbbs * ayush * nurse * others subjects * of all ages and gender, have understood the study and gave a written informed consent. exclusion criteria: subjects * cognitively impaired subjects unable to understand the study procedure

Keywords: ease of use ease of learning satisfaction
non-invasive model for fibrosis regression in hbv patients

Conditions: Chronic Hepatitis B Virus (HBV) Infection; Liver Fibrosis

Summary: a total of 1000 chronic hepatitis b (chb) patients with liver biopsy performed at least 1 year after antiviral therapy are retrospectively enrolled. all the patients received nas treatment. blood count, liver function test, alpha fetoprotein (afp), prothrombin time, liver ultrasonography, liver stiffness measurement (lsm), hepatitis b virus (hbv) dna and hbv serological markers were collected. hbv-related endpoint events, including cirrhosis decompensations (ascites, esophageal variceal bleeding and hepatic encephalopathy), hepatocellular carcinoma (hcc), liver transplantation and liver-related death were collected. fibrosis regression prediction model based on dynamic changes in liver stiffness will be developed based on the retrospective cohort. an independent cohort of chb patients with liver biopsy performed at least 1 year after antiviral therapy will be retrospectively enrolled for model validation.


Eligibility criteria:
inclusion criteria: * patients with liver biopsy performed at least 1 year after antiviral therapy; * patients with liver biopsy or liver stiffness or aspartate aminotransferase (ast)-to-platelet (plt) ratio index (apri) before antiviral treatment. exclusion criteria: * patients with decompensated cirrhosis (including ascites, hepatic encephalopathy, esophageal varices bleeding, hepatorenal syndrome, spontaneous bacterial peritonitis, or other complications of decompensated cirrhosis), hepatocellular carcinoma, or liver transplantation before liver biopsy; * patients with hepatitis c virus (hcv) or human immunodeficiency virus (hiv) infection, alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced liver injury, or other chronic liver diseases; * patients with malignant lesion on liver image; * patients with other uncured malignant tumors; * patients with severe heart, lung, kidney, brain, blood, neuropsychiatric or other organs diseases; * pregnant or lactating women; * patients with any other reasons not suitable for the study.

Keywords: chronic hepatitis b liver stiffness measurements fibrosis regression non-invasive
evaluation of intraoperative slow-release dexamethasone implant for epiretinal membrane

Conditions: Epiretinal Membrane

Summary: epiretinal membrane (erm) is a commonly encountered vitreoretinal interface anomaly with a prevalence of approximately 10% in the adult population. it is often treated with pars plana vitrectomy (ppv) and membrane peeling when symptomatic. ppv is generally successful at improving visual acuity (va) and/or metamorphopsia. at times, however, visual recovery can be hindered by macular edema in the post-vitrectomy period. ozurdex can accelerate the resorption of intraretinal edema and hasten the improvement in the visual acuity. it has been shown to facilitate fluid absorption by both stimulating endogenous adenosine signaling in muller cells and by down regulating vascular endothelial growth factor production. so, this study aim to investigate the efficacy of ozurdex implant after ppv in epiretinal membrane eyes.

small gauge pars plana vitrectomy (ppv) with membrane peeling is used to successfully treat macular epiretinal membranes (erms) with a postoperative improvement of visual acuity in the majority of cases. traditionally, the treatment of erms has been performed purely by peeling the membrane mechanically and then waiting for the intraretinal edema to resolve spontaneously. in the last few years, some publications raised the possibility that triamcinolone acetonide (ta),given as an intravitreal injection at the end of surgery, can accelerate the resorption of intraretinal edema and hasten the improvement in the visual acuity. it has been shown to facilitate fluid absorption by both stimulating endogenous adenosine signaling in muller cells and by down regulating vascular endothelial growth factor production. dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant activity 30 times that of cortisol and 6 times that of triamcinolone. as the postoperative cystoid macular edema usually peaks 4 to 6 weeks after surgery the difference in the half life can be significant and explained the results in past publications. while the use of intravitreal ta as an adjuvant to ppv with membrane peel showed conflicting results. only few publications demonstrated the effectiveness of ozurdex in the treatment of macular edema in a vitrectomized eye, after erm removal.so, this study aim to investigate the efficacy of ozurdex implant after ppv in epiretinal membrane eyes.

Eligibility criteria:
inclusion criteria: * patients with a visually significant (bcva\<20/50) idiopathic epiretinal membrane. * ocular axial length less than 27.00 mm (optical biometry) associated with cataracts. exclusion criteria: * concomitant or previous macular diseases (diabetic macular edema, retinal vein occlusion and agerelated macular degeneration). * secondary epiretinal membrane, other visually significant macular pathology and prior intravitreal triamcinolone acetonide injection.

Keywords: epiretinal membrane; ozurdex; ppv
hierarchy of effects of laboratory markers and their interaction with comorbidity concerning outcome and personalized treatment of trauma patients in emergency care and rehabilitation

Conditions: Postoperative Complications; Surgical Site Infection; Wound Infection; Non-healing Wound; Pseudarthrosis; Bone Infection; Pneumonia; Nosocomial Infection

Summary: at least ten percent of trauma patients suffer from any sort of complication. the study aims to identify a risk factor profile to early identify trauma patients at risk.

trauma patients suffer from a high risk of complications that ranges from soft tissue complications, surgical site infection till bone non-union. comorbidities are often know to be associated with complications. also certain blood markers could be identified to be an indicator. however, certain risk factors have only been investigated in small trauma cohorts so far. this study is a prospective multi center cohort trail that aims to collect all clinical data, comorbidities, medication, blood markers in trauma patients after long bone fractures. in a 6 months and one year follow up patients with complications will be identified. methods of machine learning will help to identify a risk factor profile for certain groups of patients with complications. the aim of the study is to early identify patients at risk for a complication after trauma according to their blood marker, clinical, comorbidity and medication profile.

Eligibility criteria:
inclusion criteria: * acute long bone fracture (humerus, ulna, radius, femur, tibia) with surgical treatment exclusion criteria: * associated severe injury (iss \> 16) * associated traumatic brain injury * associated traumatic spine injury * dementia

Keywords: long bone fracture, trauma
a study of qlp2117 in combination with ql2107 in advanced solid tumor patients

Conditions: Advanced Solid Tumor

Summary: the goal of this clinical trial is to evaluate the safety and efficacy of qlp2117 in combination with ql2107 in advanced solid tumor patients.


Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of recurrent or refractory advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy. * at least one measurable disease for expansion cohorts per response evaluation criteria in solid tumours (recist) v1.1(phase iba dose escalation only requires at least one assessable lesion) * eastern cooperative oncology group performance status of 0 or 1 * agree to provide archived tumor tissue samples of primary or metastatic lesions. * have adequate organ function as described in the protocol. exclusion criteria: * women who are pregnant or breastfeeding * hbsag/hbcab positive and hbv-dna\>1000 copy/ml;hcv-ab positive and detection of hcv-rna suggested viral replication * is currently participating and receiving study medication in another study within 4 week prior to the first dose of study treatment * has an active autoimmune disease that has required systemic treatment in past 2 years. * has an active infection requiring systemic therapy * has received a live vaccine wihtin 30 days of planned start of study treatment * known history of, or any evidence of interstitial lung disease
use cord blood single nucleotide polymorphism to predict the later development of atopy and allergy

Conditions: Atopy; Allergic Disease

Summary: the aim of our study was firstly to detect in cord bloods the polymorphism of genes related to atopy and allergic diseases and to examine their mutual interaction and their associations with cord blood ige and cytokines. after that, in the prospective follow-up visits, we liked to investigate if the measurement of cord blood snps of genes related to atopy and allergic diseases was helpful in predicting the development of atopy and allergic diseases later in life.


Eligibility criteria:
inclusion criteria: * apgar score of 5 minutes not less than 7 gestational age not less than 36 weeks exclusion criteria: * apgar score of 5 minutes \< 7 gestational age \< 36 weeks

Keywords: single nucleotide polymorphism
the effect of bms-986165 combined with an oral contraceptive (ethinyl estradiol/norethindrone) in healthy female patients

Conditions: Systemic Lupus Erythematosus; Arthritic Psoriasis; Psoriasis; Inflammatory Bowel Diseases

Summary: the purpose of this study is to investigate the effect of bms-986165 in combination with an oral contraceptive in healthy female patients.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 18.0 and 32.0 kg/m2 inclusive, * weight ≥ 50 kg * negative result for tuberculosis (tb) as evidenced by a quantiferon-tb gold plus test at screening, or documentation of a negative result within 4 weeks before cycle 1, day 1 * women of childbearing potential with intact ovarian function, on a stable regimen of combination birth control containing ee without evidence of clinically significant breakthrough bleeding or spotting for at least 2 consecutive months prior to cycle 1 day -1 * subjects aged 21 years or older must have a normal pap smear result within 3 years before cycle 1 day 1 (a pap smear may be performed at screening if no result is available); a finding of abnormal squamous cells of unknown significance (ascus) is allowed provided it is an initial finding and not a follow up from an initial finding of ascus exclusion criteria: * exposure to an investigational agent within 12 weeks before cycle 1 day 1 * subjects who are pregnant or breastfeeding * any significant acute or chronic medical illness including infection, any active infection, febrile illness within 7 days before cycle 1, day 1, or any condition that could predispose the subject to infection * history of recurrent or chronic sinusitis, bronchitis, pneumonia, urinary tract infection (recurrent or chronic urinary tract infection is 2 episodes within 6 months) * any serious acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months prior to screening * known or suspected autoimmune disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the subject's immune status (eg, history of splenectomy, primary immunodeficiency, etc) other protocol defined inclusion/exclusion criteria could apply
a prospective, remote observational study in pediatric participants with early-onset scn2a-developmental and epileptic encephalopathy

Conditions: SCN2A-DEE; Epilepsy

Summary: this prospective observational study is designed to assess the individualized baseline disease burden in pediatric participants aged 1 year to 16 years, with early-onset scn2a-dee by characterizing and quantifying changes in clinical features over a period of up to 12 months.


Eligibility criteria:
inclusion criteria: 1. the participant has a documented scn2a variant through genetic testing obtained via a laboratory accredited per clinical laboratory improvement amendments (clia) or college of american pathologists (cap) or equivalent. 2. the participant has onset of seizures prior to 1 month of age. 3. the participant has a phenotype consistent with a developmental and epileptic encephalopathy (dee). 4. the participant has a minimum of 8 countable motor seizures (as defined in the note below) in the 4 weeks prior to screening, as reported by the parent/guardian or in the opinion of the investigator, as documented within the medical notes. (note: motor seizures are defined as tonic, tonic-clonic, atonic/drop attacks, focal with secondary generalization, or focal with motor symptoms. myoclonic seizures or absence seizures only will not be considered as motor seizures for this study.) exclusion criteria: 1. the participant has any significant ongoing disease, disorder, laboratory abnormalities, alcohol or drug abuse or dependence, environmental factor, or any ongoing or history of any psychiatric, medical, or surgical condition that in the judgment of the investigator in consultation with the medical monitor and/or sponsor's designee, might jeopardize the participant's safety, impact the scientific objectives of the clinical study, or interfere with participation in the clinical study. 2. the participant has a clinically significant genetic variant other than an scn2a variant that may explain or contribute to the participant's epilepsy and/or developmental disorder. 3. the participant has any other or additional etiology for epilepsy and/or dee (eg, cortical dysplasia, encephalomalacia, etc), in the opinion of the investigator. 4. the participant has received any experimental or investigational drug within 30 days or 5 half lives (whichever is longer) prior to screening, including any prior use of gene therapy.

Keywords: scn2a-dee epilepsy scn2a variant pediatric epilepsy electroencephalogram developmental and epileptic encephalopathy dee
the effect of hippotherapy simulator in children with spastic cerebral palsy

Conditions: Cerebral Palsy

Summary: the horseback riding simulator (hrs) is a dynamic robotic device that mimics the movement of a horse for hippotherapy purposes. hrs aims to improve the patient's balance, adaptation and provide postural adjustment by mimicking the rhythmic movements of the horse. this study aims to research the potential benefits of the horseback riding simulator on the lower extremity selective motor control, balance and trunk control in children with cerebral palsy.

between the dates of the study, children with cerebral palsy (cp) who meet the inclusion criteria will be allocated into two groups (intervention group, control group) by randomization method. intervention group: horseback riding simulator (hrs) will be applied in addition to routine physiotherapy and rehabilitation. this group will receive 20 minutes of routine physiotherapy training and 20 minutes of hrs application in addition to 2 sessions per week for 8 weeks. control group: routine physiotherapy training will be applied within a specific programme for 40 minutes in 2 sessions per week for 8 weeks. all the assessments will be performed before and after the training in the 8-week groups.

Eligibility criteria:
inclusion criteria: * diagnosis of spastic cerebral palsy * voluntary participation * age between 5-17 years, * gmfcs level i-ii-iii * macs level i-ii-iii * modified asworth scale (mas) level 1-2-3 * have the ability to sit with support exclusion criteria: * having severe visual and hearing problems * severe distractibility problems and inability to follow task instructions, * not voluntary to participate in the research, * individuals with cp who have had hip or spine surgery in the last 6 months * individuals with cp who have undergone botox in the last 6 months

Keywords: cerebral palsy horseback riding simulator selective motor control balance